FiercePharma3d
Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama
Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies ...
pharmaphorum2d
Organon makes dermatology play with $1.2bn Dermavant buyout
Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...
Assessing Organon’s Strategic Acquisition of Dermavant: A Balanced Hold Recommendation Amid Growth and Challenges
Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of ...
Organon to buy skin therapy developer Dermavant for up to $1.2 billion
(Reuters) -Healthcare company Organon said on Wednesday it has agreed to acquire skin therapy developer Dermavant, a unit of Roivant, for up to $1.2 billion. Organon will make an upfront payment of ...
Pharmabiz1d
Organon to buy Dermavant Sciences including its innovative dermatologic therapy, Vtama cream 1% to treat plaque psoriasis
Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...
Nasdaq3d
Organon To Buy Dermavant For Around $1.2 Bln
In addition, Organon will pay Dermavant shareholders tiered royalties on net sales. The transaction is expected to be modestly dilutive to Organon's adjusted EBITDA in 2025, turning accretive in ...
Morningstar3d
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
“We look forward to combining Dermavant’s strong dermatology commercial and field medical organization in the U.S., with Organon’s market access capabilities, regulatory expertise and ...